AlgoTurk
Sign in

TRIMTECH Therapeutics Brief

Other·Targeted Protein Degraders·Seed Extension·🇬🇧

Published
📄 Read as article →

Summary

Recently raised· Seed Extension this month

Trimtech Therapeutics is an early-stage UK degrader platform commercializing TRIMTAC® and TRIMGLUE® modalities to remove toxic protein aggregates for CNS and inflammatory indications. The company has moved from concept to market credibility quickly — a $31M seed close in March 2025 followed by a $14M seed extension on June 23, 2026 (seed total $47M), a lab expansion at Babraham Research Campus (Feb 24, 2026) and placement on Fierce Biotech’s Fierce 15 (Sep 22, 2025) — and counts strategic investors including Cambridge Innovation Capital, SV Health Investors’ Dementia Discovery Fund, JJDC, BGF, Pfizer Ventures and Eli Lilly. Trimtech’s scientific wedge is explicit: co‑founders who discovered TRIM21 and a chemistry/biology leadership team focused on CNS/inflammation, plus an academic tie to the UK Dementia Research Institute. The key tension: a small, R&D-stage team and no commercial customers yet faces well‑funded degrader peers (Amphista, Plexium, Captor, Laigo, Alumis) where differentiation will hinge on TRIM21 biology translating to tractable CNS programs.

USD 259.8 million (2024)Market (TAM)
$47MTotal raised
Seed ExtensionStage
AcceleratingMomentum
CleanRisk profile

Bull case

  • Raised a combined $47M in seed funding (March 2025 $31M; June 23, 2026 $14M extension) with lead investors including Cambridge Innovation Capital, SV Health Investors’ Dementia Discovery Fund, JJDC and BGF — signal of strong investor conviction for an early R&D platform.
  • Foundational science and team edge: company is led by the academic co‑founders who discovered TRIM21, supported by senior chemistry and biology leads (e.g., Damian Crowther, PhD; Alex Alanine, PhD) and an experienced biotech CEO, aligning domain expertise with translational capability.
  • Tangible momentum and external validation: lab expansion at Babraham Research Campus (Feb 24, 2026), inclusion in Fierce Biotech’s Fierce 15 (Sep 22, 2025), and a named partnership with the UK Dementia Research Institute — all consistent with acceleration toward pharma collaborations.

Watch-outs

  • Crowded, better‑funded competitive landscape: direct peers Amphista, Plexium, Captor, Laigo and Alumis are established degrader platforms or have larger programs and capital — Trimtech must demonstrate clear, differentiated advantages from TRIMTAC/TRIMGLUE to secure partnerships.
  • No commercial revenue or customers: the company is explicitly an R&D‑stage biotech with no products sold, so value creation depends on preclinical translation, partnership deals, or future financing milestones.
  • Small organizational scale vs. program ambition: public signals show a compact operating team and advisory roster (LinkedIn size 2–10; broader team/board/SAB listed as 17+), creating execution risk if multiple CNS programs advance in parallel and require heavier bench and clinical development investment.
Crunchbase ↗LinkedIn ↗

From their website

Stats they publish

Raised $31M (£25M) seed financing (March 2025)
Named one of Fierce Biotech’s ‘Fierce 15’ (2025)
LinkedIn company size: 2-10 employees

Pricing

Not publicly disclosed. The company website does not list its pricing on any of the 6 pages we read.

Product suite

  • TRIMTACs®

    Potent, aggregate-selective degraders targeting toxic protein aggregates

  • TRIMGLUEs®

    Small-molecule degraders that harness TRIM21 to remove disease-causing protein assemblies

Target segments

Pharma BiotechResearch OrganizationsVenture Capital

Testimonials

  • “James, L.C, et al; Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function.”
    James, L.C., et al.pubmed.ncbi.nlm.nih.gov
  • “Mukadam, A.S., et al., Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.”
    Mukadam, A.S., et al.pubmed.ncbi.nlm.nih.gov
  • “Benn, J., et al., Aggregate-selective removal of pathological tau by clustering-activated degraders.”
    Benn, J., et al.pubmed.ncbi.nlm.nih.gov
  • “Miller, L.V.C., et al., Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function.”
    Miller, L.V.C., et al.pubmed.ncbi.nlm.nih.gov
  • “Mallery, D.L., et al., Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21).”
    Mallery, D.L., et al.pubmed.ncbi.nlm.nih.gov
  • “McEwan, W.A., et al., Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation.”
    McEwan, W.A., et al.pubmed.ncbi.nlm.nih.gov

Press

All news
Trade name
TRIMTECH Therapeutics Ltd.
Social
80% confidence

Crunchbase

verified profile
TRIMTECH Therapeutics LimitedActive · Private · For Profit
Heat71+34%
Growth83-11%
CB rank#4,991
Monthly visits230-75.9% MoM · as of Jun 2026
HQCambridge, Massachusetts, United States
Employees1-10
Industries
BiotechnologyMedicalTherapeutics
Technology
Common CrawlCommonCrawl Top 5m
Similar companies
Recent news
View the full profile on Crunchbase ↗

Team

Trimtech’s roster combines the academic co‑founders who discovered TRIM21, an experienced biotech CEO with prior founding and partnering track record, and senior chemistry and biology leads focused on translating TRIM21 biology into degraders.

Founder–market fit

Founders include academic originators of TRIM21 biology (Leo James and Will McEwan) and a clinician‑scientist/entrepreneur (Damian Crowther) with prior neuroscience drug‑discovery leadership—direct domain experience in TRIM21 biology and neurodegeneration.

Team read

The team pairs the academic inventors of TRIM21 with an experienced biotech CEO and drug‑discovery leads in chemistry and biology, giving strong scientific and development leadership for early translational work. The most material gap visible from public bios is no named senior commercial/head of BD hire beyond investor/board representation.

Founders & co-founders03
  • Damian Crowther, PhD FRCPCo-founder, Head of Research
  • Leo James, PhD FRSChief Scientific Adviser
  • Will McEwan, PhDCo-founder

Leadership

  • Nicki Thompson, PhDChief Executive Officer (CEO)
  • Alex Alanine, PhD MRSCSenior Vice President, Head of Chemistry
  • Andrea Testa, PhDVice President, Chemistry
  • Dean Clift, PhDSenior Director, Biology
  • Julia JonesFractional Chief Financial Officer (CFO)
  • Alison LawtonIndependent Chair
  • Alessio Ciulli, PhD FRS FRSE FRSCChair of the Scientific Advisory Board
  • Adam Gilbert, PhDMember, Scientific Advisory Board
  • Michael Anstey, PhDNon-Executive Director
  • Laurence Barker, MBA PhDNon-Executive Director
  • Marie-Claire Peakman, MRCPharm PhDNon-Executive Director
  • Hakan Goker, PhDNon-Executive Director
  • Jeffrey MooreNon-Executive Director
Advisors & boardAlessio Ciulli, PhD FRS FRSE FRSC (Chair, Scientific Advisory Board) · Adam Gilbert, PhD (Scientific Advisory Board) · Mike Hutton, PhD (Scientific Advisory Board)
SourcesHow we map the team: the founders and key leaders, taken from the company's own team page and cross-checked against public profiles.Searches we ranTrimtech Therapeutics other founder OR co-founder OR CEOTrimtech Therapeutics other leadership team OR managementTrimtech Therapeutics about us teamTrimtech Therapeutics other CTO OR COO OR CFO OR "VP Engineering" OR "Head of Product"
news-medical.net ↗trimtechtherapeutics.com ↗www2.mrc-lmb.cam.ac.uk ↗crunchbase.com ↗

Market Size

TAMTotal addressableUSD 259.8 million (2024)Grand View Research global targeted protein degradation market estimate (publisher: Grand View Research; region: Global; year: 2024).high confidence

Published market research for targeted protein degradation (TPD) is inconsistent; a focused, frequently-cited estimate from Grand View Research places the global TPD market at USD 259.8M in 2024 (projected to grow rapidly). Trimtech Therapeutics is an R&D-stage platform company with seed funding and no commercial customers or published pricing, so serviceable and obtainable market slices cannot be grounded from public records.

Cited sources
  • Grand View Research ↗The global TPD market was valued at approximately USD 259.8 million in 2024 and is expected to reach USD 794.8 million by 2030, growing at a CAGR of 20.5% from 2025 to 2030. · Global · 20.5% CAGR
  • Strategic Market Research ↗USD 970 million in 2024, growing to USD 7.25 billion by 2030, CAGR 38.1% · Global · 38.1% CAGR
  • MarketsandMarkets (reported via PR Newswire) ↗The TPD market was valued at USD 480 million in 2025 and is projected to reach USD 9.85 billion by 2035, with a CAGR of 35.4% from 2025 to 2035. · Global · 35.4% CAGR
  • Fortune Business Insights ↗USD 5.95 billion in 2025, growing to USD 12.44 billion by 2034, CAGR 9.81% (2026-2034). · Global · 9.81% CAGR
Assumptions
  • Company commercial statusR&D-stage biotech with no commercial sales or shipped productsTrimtech Therapeutics (company site; KNOWN FACTS block)
  • Recent funding / tractionRaised $31M seed financing (March 2025); later reported additional $14M bringing total seed to $47M (June 2026)Trimtech Therapeutics press releases (trimtechtherapeutics.com)
  • Reason for not producing a bottom-up SAMNo published pricing, no disclosed commercial customers or ACV on which to ground a bottom-up SAMCompany site (KNOWN FACTS) and target profile supplied
  • Published TPD market estimates vary widely by publisher and methodology; the Grand View Research figure above is one of several credible but divergent top-down estimates.
  • No reliable bottom-up SAM could be produced because Trimtech is R&D-stage with no disclosed pricing or commercial customers; SAM and SOM are therefore omitted rather than estimated.
SourcesHow we size the market: an AI web search across published market research, cross-checked against a bottom-up estimate for this company's specific space.Searches we rantargeted protein degradation market sizetargeted protein degradation market size CAGR forecastnumber of targeted protein degradation customers worldwide
polarismarketresearch.com ↗researchandmarkets.com ↗databridgemarketresearch.com ↗rootsanalysis.com ↗grandviewresearch.com ↗strategicmarketresearch.com ↗prnewswire.com ↗fortunebusinessinsights.com ↗360researchreports.com ↗trimtechtherapeutics.com ↗

Competitors

Top 5

The field clusters into degrader-platform specialists (E3-ligase modulators, glues, PROTAC-like) and indication-focused teams. Trimtech sits as an early-stage, UK-based degrader specialist targeting CNS and inflammatory disorders, suited to academic and pharma partnerships.

  • Amphista Therapeutics
    amphista.com ↗Develops Targeted Glues™ recruiting alternative E3 ligases (DCAF16, FBXO22). Trimtech overlaps on glue-like degraders but is smaller, UK-focused and earlier-stage with CNS/inflammation emphasis.
  • Plexium
    plexium.com ↗Focuses on small-molecule E3 ligase modulators and high-throughput degrader discovery. Trimtech competes on degrader modality but differentiates via TRIMTAC/TRIMGLUE platform and CNS/inflammation target set.
  • Captor Therapeutics
    captortherapeutics.com ↗Develops targeted protein degradation programs across oncology and autoimmune indications. Trimtech is narrower on CNS/inflammation and earlier-stage, positioning for neuroscience-focused partnerships.
  • Laigo Bio
    laigobio.com ↗Works on targeted protein degradation discovery and therapeutics. Trimtech is a direct peer but distinguishes itself with TRIMTAC/TRIMGLUE branding and UK academic partnerships (e.g., UK Dementia Research Institute).
  • Alumis (fka Esker Therapeutics)
    alumis.com ↗Centers on precision therapies for autoimmune disease; listed among degradation players. Trimtech is more explicitly degrader-first with R&D-stage CNS/inflammation programs.
SourcesHow we find competitors: an AI web search for the company's closest rivals and how it's positioned against them. Each name is verified before it's listed.Searches we ranTrimtech Therapeutics targeted protein degradation alternativesTrimtech Therapeutics targeted protein degradation competitorstargeted protein degradation companies like Trimtech Therapeutics
clarivate.com ↗thepharmaletter.com ↗linkedin.com ↗mrclmb.ac.uk ↗ddw-online.com ↗

Funding

Total raised$47M
From Crunchbase ↗
  • Seed Round$31 million (£25 million)Mar 5, 2025
    Cambridge Innovation Capital leadDementia Discovery Fund leadSV Health Investors’ Dementia Discovery Fund leadEli LillyCambridge Enterprise VenturesMP Healthcare Venture ManagementStart CodonM VenturesPfizer Venture InvestmentsPfizer VenturesEli Lilly and CompanyMP Healthcare Venture Management (MPH)
    Trimtech Therapeutics (company press release) ↗
  • Seed Round
    Johnson & Johnson Innovation leadCambridge Enterprise VenturesCambridge Innovation CapitalSV Health InvestorsM VenturesEli LillyPfizer Venture InvestmentsBusiness Growth FundMP Healthcare Venture Management
    Crunchbase ↗
  • Seed Extension$14 millionJun 23, 2026
    Johnson & Johnson Innovation – JJDC, Inc. leadBGF leadCambridge Innovation CapitalDementia Discovery FundM VenturesPfizer VenturesEli Lilly and CompanyMP Healthcare Venture Management (MPH)Cambridge Enterprise Ventures
    BioSpace (businesswire press release) ↗

Trimtech Therapeutics completed a $31M seed close in March 2025 (led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund) and announced a $14M seed extension on 23 June 2026 led by Johnson & Johnson Innovation (JJDC) and BGF, bringing the seed total to $47M.

  • Crunchbase's structured record lists investors and two rounds but does not include full per-round amounts in the embedded feed; PitchBook shows a similar aggregate figure (reporting $31.7M) and Tracxn lists $31M — public press and the company press releases above are the primary sources for the $31M and $14M figures.
  • Some third-party trackers report rounded or slightly different totals (e.g. $31.7M); the itemized rounds and total here follow the company press release and corroborating press coverage.
SourcesHow we track funding: an AI web search across funding databases and press for disclosed rounds, amounts and investors. Conflicting totals are reconciled to the best-evidenced figure.Searches we ranTrimtech Therapeutics funding round raisedTrimtech Therapeutics investorsTrimtech Therapeutics seed roundTrimtech Therapeutics targeted-protein-degradation fundingTrimtech Therapeutics funding 2026
biospace.com ↗news-medical.net ↗enterprise.cam.ac.uk ↗international-biopharma.com ↗eu-startups.com ↗crunchbase.com ↗bebeez.eu ↗

Momentum

TrajectoryAccelerating

TRIMTECH Therapeutics has shown accelerating momentum across 2025–2026: it closed a $31M seed on March 5, 2025, was named to Fierce Biotech’s 'Fierce 15' on September 22, 2025, expanded into new lab space at Babraham Research Campus (Feb 24, 2026), and announced a $14M seed extension on June 23, 2026 bringing the total to $47M.

  • Most items are company press releases and coverage of those releases; independent investigative reporting is limited.
SourcesHow we read momentum: an AI web search for recent dated signals — funding, hires, launches and partnerships — with same-name companies filtered out.Searches we ranTrimtech Therapeutics news announcementTrimtech Therapeutics 2026Trimtech Therapeutics funding investment round 2026Trimtech Therapeutics targeted-protein-degradation launch partnership
finsmes.com ↗businesswire.com ↗marketscreener.com ↗european-biotechnology.com ↗morningstar.com ↗bdaily.co.uk ↗pharmiweb.com ↗businessweekly.co.uk ↗bebeez.eu ↗m-ventures.com ↗

Customer Sentiment

Public third-party coverage of Trimtech Therapeutics is limited to press pieces, investor/portfolio listings and company profile pages describing its TRIMTAC/TRIMGLUE degrader technology, seed funding and awards; there are no customer or patient reviews or platform ratings that provide user sentiment.

Not enough public customer reviews to judge sentiment — common for early-stage, pre-commercial or B2B biotech companies.

AI Visibility

We ask ChatGPT WITH web search about the company and show its answers plus the sources it cited — the real AI-search experience. The key signal is share of voice: does the company come up when AI is asked about its space, not just when asked by name.

Models asked ChatGPT · web search

AI awarenessStrong

Accuracy of what AI said: Accurate — Correctly identifies Trimtech Therapeutics as a Cambridge-based biotech developing TRIMTAC®/TRIMGLUE® platforms targeting TRIM21, and lists founders, seed funding, and recognition consistent with public materials.

ChatGPT · web searchFound
QWhat do you know about Trimtech Therapeutics, the company at trimtechtherapeutics.com? What do they do, who founded it, size/stage, and any notable facts? Cite your sources.
A

Trimtech Therapeutics is a biotechnology company based in Cambridge, UK, specializing in developing small molecule therapeutics that selectively degrade disease-causing protein aggregates associated with neurodegenerative and inflammatory disorders. Their proprietary platforms, TRIMTACs® and TRIMGLUEs®, harness the E3 ubiquitin ligase TRIM21 to target and eliminate toxic protein assemblies while preserving the functional forms of these proteins, thereby maintaining healthy cellular function. (trimtechtherapeutics.com)

Founders and Leadership: The company was founded in 2023 by Dr. Leo James, Group Leader at the MRC Laboratory of Molecular Biology, and Dr. William McEwan, Group Leader at the UK Dementia Research Institute, University of Cambridge. Both have conducted over 15 years of pioneering research into the biology of TRIM21. (trimtechtherapeutics.com) As of December 2025, Alison Lawton serves as the Chair of the Board. (trimtechtherapeutics.com)

Funding and Growth: In March 2025, Trimtech Therapeutics secured a $31 million (£25 million) seed funding round led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund, with participation from M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures, and Start Codon. (trimtechtherapeutics.com) By June 2026, the company raised an additional $14 million, bringing the total seed funding to $47 million.

Notable Achievements: In September 2025, Trimtech Therapeutics was recognized as one of Fierce Biotech’s ‘Fierce 15’ companies, highlighting its innovation and promise in the biotechnology sector. (m-ventures.com)

Company Size and Stage: As of June 2026, Trimtech Therapeutics is a privately held company in the growth stage, with a team comprising world-renowned scientists, experienced entrepreneurs, and executives from the pharmaceutical and biotech industries. (trimtechtherapeutics.com)

For more detailed information, you can visit their official website:

Sources AI citedtrimtechtherapeutics.com ↗trimtechtherapeutics.com ↗trimtechtherapeutics.com ↗m-ventures.com ↗
ChatGPT · web searchAmong leaders
QWho are the most notable companies or products in the targeted-protein-degraders space? Give a concise list with one line each, and cite your sources.
A

The targeted protein degradation (TPD) field features several notable companies and products:

  • Arvinas: Pioneered PROTAC technology with clinical candidates ARV-110 (androgen receptor degrader) and ARV-471 (estrogen receptor degrader). (marketsandmarkets.com)
  • Bristol Myers Squibb (BMS): Leads in molecular glue-based protein degradation, focusing on oncology and immunology, with programs like CC-90009 and Revlimid. (marketsandmarkets.com)
  • Kymera Therapeutics: Develops oral small-molecule degraders targeting immunology, inflammation, and oncology, including KT-474 (IRAK4 degrader). (marketsandmarkets.com)
  • Nurix Therapeutics: Specializes in E3 ligase modulation and PROTACs, with programs like NX-2127 (BTK degrader) and NX-5948 (BTK degrader). (rfemerge.com)
  • C4 Therapeutics: Utilizes its TORPEDO platform to develop targeted protein degraders for hematologic cancers and solid tumors, including CFT7455 (IKZF1/3 degrader). (marketsandmarkets.com)
  • Monte Rosa Therapeutics: Focuses on molecular glues, with programs like MRT-6160 targeting VAV1 for T and B cell modulation. (rfemerge.com)
  • Foghorn Therapeutics: Develops BRD9 degraders, including FHD-609 and FHD-909, for oncology applications. (rfemerge.com)
  • Pfizer: Engages in various TPD strategies through internal discovery programs and external licensing. (rfemerge.com)
  • Merck KGaA: Provides reagents, kits, and analytical tools essential for degrader discovery and validation. (grandviewresearch.com)
  • Thermo Fisher Scientific: Supplies instruments, reagents, and proteomics solutions supporting TPD research workflows. (grandviewresearch.com)

These companies are at the forefront of advancing targeted protein degradation therapies.

Sources AI citedmarketsandmarkets.com ↗marketsandmarkets.com ↗rfemerge.com ↗grandviewresearch.com ↗
ChatGPT · web searchRecommended
QIf someone asked you to recommend companies or products in the targeted-protein-degraders space, who would you name? Cite your sources.
A

Targeted protein degradation (TPD) is an innovative therapeutic approach that involves selectively eliminating disease-causing proteins. Several companies are at the forefront of this field, developing novel therapies and technologies. Here are some notable organizations:

Arvinas Inc. Arvinas is a pioneer in the TPD field, recognized for being the first company to bring a PROTAC (PROteolysis TArgeting Chimera) degrader into clinical trials. Their clinical pipeline includes ARV-110 and ARV-471, targeting androgen and estrogen receptors in prostate and breast cancers, respectively. Arvinas has also formed high-profile collaborations with Pfizer and Bayer to explore new targets and therapeutic areas beyond oncology. (marketsandmarkets.com)

C4 Therapeutics Founded in 2015, C4 Therapeutics has established itself as a leader in TPD science. They are progressing targeted oncology programs through clinical studies and leveraging their TORPEDO® platform to design and optimize small-molecule medicines for difficult-to-treat diseases. (c4therapeutics.com)

Kymera Therapeutics Inc. Kymera Therapeutics focuses on developing small molecule drugs that harness the body's natural protein degradation mechanisms to selectively degrade disease-causing proteins. Their pipeline includes KT-474, an IRAK4 degrader, with collaborations involving Sanofi and Vertex. (rfemerge.com)

Monte Rosa Therapeutics Inc. Monte Rosa Therapeutics specializes in molecular glues, a class of small molecules that induce protein degradation. Their lead program, MRT-6160, targets VAV1, a protein involved in T and B cell modulation. They have a collaboration with Novartis to explore undrugged proteins. (rfemerge.com)

Nurix Therapeutics Inc. Nurix Therapeutics is developing therapies that modulate E3 ligases, enzymes involved in protein degradation. Their pipeline includes GS-6791 (IRAK4 degrader), NX-2127 (BTK degrader), and NX-5948 (BTK degrader), with partnerships involving Gilead, Sanofi, and Seagen. (rfemerge.com)

PhoreMost PhoreMost is a biotech company expanding the potential of TPD through novel mini-protein engineering and proprietary platforms like SITESEEKER® and GlueSEEKER®. They have established strategic partnerships with Roche, Boehringer Ingelheim, and Sentinel Oncology. (amadeuscapital.com)

Bristol Myers Squibb (BMS) BMS was among the earliest large pharmaceutical companies to recognize the potential of TPD, particularly through molecular glues that reprogram E3 ligases to degrade disease-causing proteins. They continue to build a robust pipeline of TPD candidates, especially in oncology and immunology. (marketsandmarkets.com)

These companies are leading the advancement of targeted protein degradation therapies, offering promising avenues for treating various diseases.

Sources AI citedmarketsandmarkets.com ↗c4therapeutics.com ↗rfemerge.com ↗amadeuscapital.com ↗

The AI surfaced Trimtech Therapeutics unprompted when listing notable targeted-protein-degrader companies and recommended it among peers; its direct description of the company aligns with the public profile and can be relied on for high-level diligence.

  • AI answers can vary run-to-run and may omit recent developments in other queries.
  • Public web coverage for early-stage companies can be limited; verify funding and leadership from official filings or the company site for transaction-level diligence.

Risks & Red Flags

No material public risk signals found. An absence of public concerns isn’t a clean bill of health — early or private companies may simply not generate coverage.

An absence of public reporting is not a clean bill of health; early-stage, private biotechs frequently have limited public records and risks may exist that are not publicly disclosed.

Sources reviewedHow we check for red flags: an AI web search for any publicly reported lawsuits, regulatory action, negative press, layoffs or security incidents about this specific company. Only verifiable, clearly-attributed concerns are shown — and an absence of findings isn't a clean bill of health.Searches we ranSearch NEWS, regulators, courts and watchdog reports for publicly reported RISKS or red flags about Trimtech Therapeutics (the company at trimtechtherapeutics.com — Developing selective protein-degrading therapeutics (TRIMTACs and TRIMGLUEs) to treat CNS and inflammatory disorders.). Look for: lawsuits or legal disputes; regulatory actions, fines, investigations or bans; negative press or controversy; distress signals (layoffs, shutdown, key-executive departures, funding trouble); security incidents (data breach, hack, major outage); and serious customer complaints or fraud/scam allegations. Use INDEPENDENT third-party sources — news outlets, regulators, courts, reputable trade press — NOT trimtechtherapeutics.com's own website or company-owned blogs. Check Global sources. Make sure every result is about THIS company, not a different organization with a similar name. Cite each source. If genuinely nothing material is found, say so.

Frequently asked questions

What does TRIMTECH Therapeutics do?

Developing selective protein-degrading therapeutics (TRIMTACs® and TRIMGLUEs®) to treat CNS and inflammatory disorders by removing toxic protein aggregates.

How much funding has TRIMTECH Therapeutics raised?

TRIMTECH Therapeutics has raised $47M in disclosed funding. Its most recent disclosed round was a $14 million Seed Extension in 2026, led by Johnson & Johnson Innovation – JJDC, Inc. and BGF.

Who are TRIMTECH Therapeutics's main competitors?

TRIMTECH Therapeutics's named competitors include Amphista Therapeutics, Plexium, Captor Therapeutics and Laigo Bio.

Who founded TRIMTECH Therapeutics?

TRIMTECH Therapeutics was founded by Damian Crowther, PhD FRCP, Leo James, PhD FRS and Will McEwan, PhD.

Where is TRIMTECH Therapeutics headquartered?

TRIMTECH Therapeutics is headquartered in Cambridge, United Kingdom.

What market does TRIMTECH Therapeutics operate in?

TRIMTECH Therapeutics operates in the Targeted protein degraders market (B2B). Its total addressable market is estimated at USD 259.8 million (2024).

How does TRIMTECH Therapeutics's pricing work?

TRIMTECH Therapeutics uses a unknown pricing model.

Compiled by AlgoTurk from public web sources · . Not investment advice.

TRIMTECH Therapeutics — Funding, Competitors & Research Brief · AlgoTurk